Management of Spontaneous Intracerebral Hemorrhage

Research output: Contribution to journalArticle

Abstract

Spontaneous intracerebral hemorrhage (ICH) has the highest mortality of all cerebrovascular events. Thirty-day mortality approaches 50%, and only 20% of survivors achieve meaningful functional recovery at 6 months. Many clinicians believe that effective therapies are lacking; however, this is changing because of new data on the pathophysiology and treatment of ICH, particularly research establishing the role of medical therapies to promote hematoma stabilization. This article provides updates to a recent publication discussing basic principles of ICH management, including initial stabilization, the prevention of hematoma growth, treatment of complications, and identification of the underlying etiology. Minimally invasive surgery (MIS) to reduce clot size is also discussed, with the goal of preserving neurologic function through reduction in parenchymal damage from edema formation.

Original languageEnglish (US)
Pages (from-to)373-384
Number of pages12
JournalNeurologic Clinics
Volume26
Issue number2
DOIs
StatePublished - May 2008

Fingerprint

Cerebral Hemorrhage
Hematoma
Minimally Invasive Surgical Procedures
Mortality
Therapeutics
Nervous System
Survivors
Edema
Growth
Research

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Management of Spontaneous Intracerebral Hemorrhage. / Naval, Neeraj S.; Nyquist, Paul A; Carhuapoma, Juan.

In: Neurologic Clinics, Vol. 26, No. 2, 05.2008, p. 373-384.

Research output: Contribution to journalArticle

@article{f6388eeafc894beebf1e4b92c3b00697,
title = "Management of Spontaneous Intracerebral Hemorrhage",
abstract = "Spontaneous intracerebral hemorrhage (ICH) has the highest mortality of all cerebrovascular events. Thirty-day mortality approaches 50{\%}, and only 20{\%} of survivors achieve meaningful functional recovery at 6 months. Many clinicians believe that effective therapies are lacking; however, this is changing because of new data on the pathophysiology and treatment of ICH, particularly research establishing the role of medical therapies to promote hematoma stabilization. This article provides updates to a recent publication discussing basic principles of ICH management, including initial stabilization, the prevention of hematoma growth, treatment of complications, and identification of the underlying etiology. Minimally invasive surgery (MIS) to reduce clot size is also discussed, with the goal of preserving neurologic function through reduction in parenchymal damage from edema formation.",
author = "Naval, {Neeraj S.} and Nyquist, {Paul A} and Juan Carhuapoma",
year = "2008",
month = "5",
doi = "10.1016/j.ncl.2008.03.002",
language = "English (US)",
volume = "26",
pages = "373--384",
journal = "Neurologic Clinics",
issn = "0733-8619",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Management of Spontaneous Intracerebral Hemorrhage

AU - Naval, Neeraj S.

AU - Nyquist, Paul A

AU - Carhuapoma, Juan

PY - 2008/5

Y1 - 2008/5

N2 - Spontaneous intracerebral hemorrhage (ICH) has the highest mortality of all cerebrovascular events. Thirty-day mortality approaches 50%, and only 20% of survivors achieve meaningful functional recovery at 6 months. Many clinicians believe that effective therapies are lacking; however, this is changing because of new data on the pathophysiology and treatment of ICH, particularly research establishing the role of medical therapies to promote hematoma stabilization. This article provides updates to a recent publication discussing basic principles of ICH management, including initial stabilization, the prevention of hematoma growth, treatment of complications, and identification of the underlying etiology. Minimally invasive surgery (MIS) to reduce clot size is also discussed, with the goal of preserving neurologic function through reduction in parenchymal damage from edema formation.

AB - Spontaneous intracerebral hemorrhage (ICH) has the highest mortality of all cerebrovascular events. Thirty-day mortality approaches 50%, and only 20% of survivors achieve meaningful functional recovery at 6 months. Many clinicians believe that effective therapies are lacking; however, this is changing because of new data on the pathophysiology and treatment of ICH, particularly research establishing the role of medical therapies to promote hematoma stabilization. This article provides updates to a recent publication discussing basic principles of ICH management, including initial stabilization, the prevention of hematoma growth, treatment of complications, and identification of the underlying etiology. Minimally invasive surgery (MIS) to reduce clot size is also discussed, with the goal of preserving neurologic function through reduction in parenchymal damage from edema formation.

UR - http://www.scopus.com/inward/record.url?scp=44349137733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44349137733&partnerID=8YFLogxK

U2 - 10.1016/j.ncl.2008.03.002

DO - 10.1016/j.ncl.2008.03.002

M3 - Article

C2 - 18514818

AN - SCOPUS:44349137733

VL - 26

SP - 373

EP - 384

JO - Neurologic Clinics

JF - Neurologic Clinics

SN - 0733-8619

IS - 2

ER -